Guess which ASX biotech stock is rocketing 28% on 'extremely encouraging' Alzheimer's data

Alzheimer's Disease accounts for 60% to 70% of all cases of dementia.

A group of medical researchers stands side by side with each other wearing white coats in their research laboratory with scientific equipment in the background.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Argenica Therapeutics shares are up 28% in afternoon trade
  • The ASX biotech stock reported promising preclinical results to treat Alzheimer’s Disease
  • The global Alzheimer’s Disease therapeutics market size was valued at US$4 billion in 2021

ASX biotech stock Argenica Therapeutics Ltd (ASX: AGN) is off to the races today.

Shares in the biotechnology company closed yesterday trading at 41 cents and are currently swapping hands for 52 cents apiece, up 28.4%.

Here's what's piquing ASX investor interest today.

What did the ASX biotech stock report?

Argenica Therapeutics shares are rocketing after the ASX biotech stock reported promising results with its lead neuroprotective peptide candidate, ARG-007, in an in vitro preclinical study.

According to the company's release, the preclinical results indicated ARG-007 "significantly inhibits the aggregation of human recombinant Amyloid-Beta (Abeta) in a cell-free Abeta aggregation assay model".

That could prove to be great news for patients suffering from Alzheimer's Disease, which accounts for 60% to 70% of all cases of dementia. Abeta aggregation is believed to be one of the main causes of Alzheimer's, with the Abeta accumulation in senile plaques causing memory loss and confusion.

Argenica reported that Abeta aggregation was reduced by more than 50% compared to vehicle controls 16 hours following a 25 µM dose of ARG-007.

Commenting on the results sending the ASX biotech stock soaring today, Argenica managing director Liz Dallimore said:

This is extremely encouraging data showing a potential new indication for ARG-007. It is well recognised that Abeta aggregation in the brain plays a key role in initiating Alzheimer's Disease, and therefore a safe therapeutic drug that can reduce Abeta aggregation is a huge opportunity.

We look forward to continuing to progress this exciting opportunity into further animal studies.

Argenica noted that the global Alzheimer's Disease therapeutics market size was valued at some US$4 billion in 2021. That's expected to increase at a compound annual growth rate (CAGR) of 16.2% from 2022 to 2030.

Argenica Therapeutics share price snapshot

Today's big leap has put the Argenica Therapeutics share price back in the green for 2023, up 16%. As you can see in the chart below, the ASX biotech stock remains down 28% over the past 12 months.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the 'five best ASX stocks' for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now...

See The 5 Stocks *Returns as of 30 April 2025

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Should I buy the dip on CSL shares?

A leading fund manager gives his verdict on the growth prospects for CSL shares.

Read more »

A woman relaxes on a yellow couch with a book and cuppa, and looks pensively away as she contemplates the joy of earning passive income.
Healthcare Shares

NIB shares have soared 24% this year. Does Macquarie expect this to continue?

Will this private health insurer continue to deliver big returns? Let's find out.

Read more »

Woman presenting financial report on large screen in conference room.
Healthcare Shares

Up nearly 30% in a year, should I buy Fisher & Paykel shares before its earnings result?

Will the ASX 200 healthcare stock continue to outperform?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL shares among most expensive on ASX. Is now a good time to buy?

Analysts predict CSL share price growth will keep on coming.

Read more »

A man looking at his laptop and thinking.
Healthcare Shares

Should you buy the dip in the ResMed share price?

Let's see what one leading broker is saying following yesterday's pullback.

Read more »

A woman puts up her hands and looks confused while sitting at her computer.
Healthcare Shares

Down 5%: What's going on with the ResMed share price?

Let's see what has spooked investors today and caused them to push the sell button.

Read more »

Beautiful young woman drinking fresh orange juice in kitchen.
Healthcare Shares

Guess which ASX 300 stock is jumping 11% on big news

This stock is having a day to remember on Thursday. But why?

Read more »

A group of medical researchers stands side by side with each other wearing white coats in their research laboratory with scientific equipment in the background.
Healthcare Shares

Trump executive order to hit these 3 ASX pharmaceutical stocks

Donald Trump’s new executive order caused these 3 ASX pharmaceutical stocks to crash on Monday.

Read more »